LATEST TWEETS - CURATED BY HASH FINANCE

Kiniksa Pharmaceuticals $KNSA Upgraded at BidaskClub https://t.co/0YfCHkri77
Kiniksa Pharmaceuticals $KNSA Upgraded at BidaskClub https://t.co/ThH7vwmMKH
Kiniksa Pharmaceuticals $KNSA Upgraded at BidaskClub https://t.co/ruzo5rUIv9
Kiniksa Pharmaceuticals $KNSA Upgraded to Sell at BidaskClub https://t.co/rnu6rXe63S
Kiniksa Pharmaceuticals Ltd $KNSA Short Interest Update https://t.co/RmdvHXMX82
Tickeron (Tickeron) 2 days ago
$KNSA in Uptrend: RSI indicator exits oversold zone. View odds for this and other indicators:… https://t.co/gzO8r5nmkq
Kiniksa Pharmaceuticals $KNSA Upgraded by BidaskClub to “Sell” https://t.co/sp7I0UDkAJ
.@kiniksa's mavrilimumab received FDA orphan drug designation for the treatment of giant cell arteritis (GCA) $KNSA https://t.co/mhjwNPVOFY
Kiniksa Announces U.S. Orphan Drug Designation for Mavrilimumab for the Treatment of Giant Cell Arteritis $KNSA https://t.co/7YHUmDVDol
Kiniksa Pharmaceuticals $KNSA Stock Rating Upgraded by BidaskClub https://t.co/gwGuVd22aX
We are pleased to announce we have received Orphan Drug Designation from the U.S. FDA for #mavrilimumab, our invest… https://t.co/aXE7R6Xf9N
░Λlgo Bot (sbwcws) 4 days ago
Kiniksa treatment of Giant Cell Arteritis granted FDA orphan designation $KNSA
$KNSA: Kiniksa Pharmaceuticals granted FDA Orphan Drug designation for mavrilimumab for the treatment of giant cell… https://t.co/tcELVmQn2a
$KNSA Kiniksa Announces U.S. Orphan Drug Designation for Mavrilimumab for the Treatment of Giant Cell Arteritis https://t.co/wwjvtoRuUj
Preticks (preticks) 4 days ago
Latest headline: (NASDAQ $KNSA) Kiniksa Announces U.S. Orphan Drug Designation for Mavrilimumab for the Treatment o… https://t.co/VgXPovY0t1
dough (semodough) 4 days ago
$KNSA Kiniksa Announces U.S. Orphan Drug Designation for Mavrilimumab for the Treatment of Giant Cell Arteritis | K… https://t.co/ydFO8S085d
19,000 shares acquired by Megna Michael R (Chief Accounting Officer), reported in a new form 4 filed with the SEC… https://t.co/LBmHhvobWe
75,000 shares acquired by Rizvi Qasim (Chief Commercial Officer), reported in a new form 4 filed with the SEC $KNSA https://t.co/3xsyK5yAWv
50,000 shares acquired by Paolini John F. (SVP & Chief Medical Officer), reported in a new form 4 filed with the SE… https://t.co/4kYsPYgOGu
Tickeron (Tickeron) 5 days ago
$KNSA's Aroon indicator drops into Downtrend on September 11, 2020. View odds for this and other indicators:… https://t.co/GfkaUU3RXL
$KNSA [15s. delayed] filed SEC form 4: Chairman & CEO Patel Sanj K: Transacted Derivative Securities on 2020-09-10… https://t.co/YiaQpqi6K2
$KNSA [15s. delayed] filed SEC form 4: EVP & Chief Legal Officer Beetham Thomas W.: Transacted Derivative Securiti… https://t.co/HZd2Bk9ZTf
75,000 shares acquired by Beetham Thomas W. (EVP & Chief Legal Officer), reported in a new form 4 filed with the SE… https://t.co/a46cyP1Oof
$KNSA [15s. delayed] filed SEC form 4: SVP & Chief Medical Officer Paolini John F.: Transacted Derivative Securiti… https://t.co/s42qfeLwfM
$KNSA [15s. delayed] filed SEC form 4: Chief Commercial Officer Rizvi Qasim: Transacted Derivative Securities on 2… https://t.co/6EtpXCsPaT
$KNSA [15s. delayed] filed SEC form 4: Chief Accounting Officer Megna Michael R: Transacted Derivative Securities… https://t.co/OhESPOaoD2